Clinical Trials Arena January 31, 2025
Okuzawa has been with the company since 1986.
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025.
The company’s board of directors followed the nomination committee’s report, appointing Okuzawa to ensure the achievement of the year’s goals and strengthen its management structure.
The strategic move comes as the company gears up for the final year of its current five-year business plan in 2025, and prepares for the subsequent plan for the financial years 2026 (FY26) to FY30.
Hiroyuki has served as president, representative director and chief operating officer (COO) since 2023, and as chief financial officer for two years. He has been with the company since 1986.
He has been instrumental...
Today's Sponsors
Today's Sponsor